|
1
|
Dowsett M: Preoperative models to evaluate
endocrine strategies for breast cancer. Clin Cancer Res.
9:502S–510S. 2003.PubMed/NCBI
|
|
2
|
Youness RA, Gad AZ, Sanber K, Ahn YJ, Lee
GJ, Khallaf E, Hafez HM, Motaal AA, Ahmed N and Gad MZ: Targeting
hydrogen sulphide signaling in breast cancer. J Adv Res.
27:177–190. 2020.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Viedma-Rodríguez R, Baiza-Gutman L,
Salamanca-Gómez F, Diaz-Zaragoza M, Martínez-Hernández G, Ruiz
Esparza-Garrido R, Velázquez-Flores MA and Arenas-Aranda D:
Mechanisms associated with resistance to tamoxifen in estrogen
receptor-positive breast cancer (review). Oncol Rep. 32:3–15.
2014.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Chen L, Duan Y, Wei H, Ning H, Bi C, Zhao
Y, Qin Y and Li Y: Acetyl-CoA carboxylase (ACC) as a therapeutic
target for metabolic syndrome and recent developments in ACC1/2
inhibitors. Expert Opin Investig Drugs. 28:917–930. 2019.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Corbett JW: Review of recent acetyl-CoA
carboxylase inhibitor patents: Mid-2007-2008. Expert Opin Ther Pat.
19:943–956. 2009.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Zhan Y, Ginanni N, Tota MR, Wu M, Bays NW,
Richon VM, Kohl NE, Bachman ES, Strack PR and Krauss S: Control of
cell growth and survival by enzymes of the fatty acid synthesis
pathway in HCT-116 colon cancer cells. Clin Cancer Res.
14:5735–5742. 2008.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Zhao S, Cheng L, Shi Y, Li J, Yun Q and
Yang H: MIEF2 reprograms lipid metabolism to drive progression of
ovarian cancer through ROS/AKT/mTOR signaling pathway. Cell Death
Dis. 12(18)2021.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Ye B, Yin L, Wang Q and Xu C: ACC1 is
overexpressed in liver cancers and contributes to the proliferation
of human hepatoma Hep G2 cells and the rat liver cell line BRL 3A.
Mol Med Rep. 19:3431–3440. 2019.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Fang W, Cui H, Yu D, Chen Y, Wang J and Yu
G: Increased expression of phospho-acetyl-CoA carboxylase protein
is an independent prognostic factor for human gastric cancer
without lymph node metastasis. Med Oncol. 31(15)2014.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408.
2001.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Zhou J, Chen C, Zhao X, Jiang T, Jiang Y,
Dai J and Chen J: Coding variants in the PCNT and CEP295 genes
contribute to breast cancer risk in Chinese women. Pathol Res
Pract. 225(153581)2021.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Miller EA, Pinsky PF, Heckman-Stoddard BM
and Minasian LM: Breast cancer risk prediction models and
subsequent tumor characteristics. Breast Cancer. 27:662–669.
2020.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Rysman E, Brusselmans K, Scheys K,
Timmermans L, Derua R, Munck S, Van Veldhoven PP, Waltregny D,
Daniëls VW, Machiels J, et al: De novo lipogenesis protects cancer
cells from free radicals and chemotherapeutics by promoting
membrane lipid saturation. Cancer Res. 70:8117–8126.
2010.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Schreurs M, Kuipers F and van der Leij FR:
Regulatory enzymes of mitochondrial beta-oxidation as targets for
treatment of the metabolic syndrome. Obes Rev. 11:380–388.
2010.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Harwood HJ Jr: Treating the metabolic
syndrome: Acetyl-CoA carboxylase inhibition. Expert Opin Ther
Targets. 9:267–281. 2005.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Savage DB, Choi CS, Samuel VT, Liu ZX,
Zhang D, Wang A, Zhang XM, Cline GW, Yu XX, Geisler JG, et al:
Reversal of diet-induced hepatic steatosis and hepatic insulin
resistance by antisense oligonucleotide inhibitors of acetyl-CoA
carboxylases 1 and 2. J Clin Invest. 116:817–824. 2006.PubMed/NCBI View
Article : Google Scholar
|
|
17
|
Kusunoki J, Kanatani A and Moller DE:
Modulation of fatty acid metabolism as a potential approach to the
treatment of obesity and the metabolic syndrome. Endocrine.
29:91–100. 2006.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Srivastava RA, Jahagirdar R, Azhar S,
Sharma S and Bisgaier CL: Peroxisome proliferator-activated
receptor-alpha selective ligand reduces adiposity, improves insulin
sensitivity and inhibits atherosclerosis in LDL receptor-deficient
mice. Mol Cell Biochem. 285:35–50. 2006.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Pang B, Zhang J, Zhang X, Yuan J, Shi Y
and Qiao L: Inhibition of lipogenesis and induction of apoptosis by
valproic acid in prostate cancer cells via the C/EBPα/SREBP-1
pathway. Acta Biochim Biophys Sin (Shanghai). 53:354–364.
2021.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Göbel A, Dell'Endice S, Jaschke N, Pählig
S, Shahid A, Hofbauer LC and Rachner TD: The role of inflammation
in breast and prostate cancer metastasis to bone. Int J Mol Sci.
22(5078)2021.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Tong D: Unravelling the molecular
mechanisms of prostate cancer evolution from genotype to phenotype.
Crit Rev Oncol Hematol. 163(103370)2021.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Barik GK, Sahay O, Behera A, Naik D and
Kalita B: Keep your eyes peeled for long noncoding RNAs: Explaining
their boundless role in cancer metastasis, drug resistance, and
clinical application. Biochim Biophys Acta Rev Cancer.
1876(188612)2021.PubMed/NCBI View Article : Google Scholar
|
|
23
|
González-Martínez S, Pérez-Mies B, Pizarro
D, Caniego-Casas T, Cortés J and Palacios J: Epithelial mesenchymal
transition and immune response in metaplastic breast carcinoma. Int
J Mol Sci. 22(7398)2021.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Lu Y, Ding Y, Wei J, He S, Liu X, Pan H,
Yuan B, Liu Q and Zhang J: Anticancer effects of traditional
chinese medicine on epithelial-mesenchymal transition (EMT) in
breast cancer: Cellular and molecular targets. Eur J Pharmacol.
907(174275)2021.PubMed/NCBI View Article : Google Scholar
|
